Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

New England Journal of Medicine

Volumn 372, Issue 16, 2015, Pages 1489-1499

  Robinson, Jennifer G ^a   Farnier, Michel ^b   Krempf, Michel ^c   Bergeron, Jean ^f   Luc, Gérald ^d   Averna, Maurizio ^g   Stroes, Erik S ^h   Langslet, Gisle ⁱ   Raal, Frederick J ^j   El Shahawy, Mahfouz ^k   Koren, Michael J ^l   Lepor, Norman E ^m   Lorenzato, Christelle ^e   Pordy, Robert ⁿ   Chaudhari, Umesh ^e   Kastelein, John J P ^h  

^a UNIVERSITY OF IOWA   (United States)

^b Point Medical   (France)

^c CHU de Nantes   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e SANOFI   (France)

^f Clinique des Maladies Lipidiques de Quebec Incorporated   (Canada)

^g UNIVERSITY OF PALERMO   (Italy)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k Heart Center of Sarasota   (United States)

^l Jacksonville Center for Clinical Research   (United States)

^m Westside Medical Asocats of Los Angeles   (United States)

ⁿ REGENERON PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INJECTION SITE REACTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; HYPERCHOLESTEROLEMIA; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

AGED; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED;

EID: 84926191670     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1501031     Document Type: Article

References (11)

1. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53.
2. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891-900.
3. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380: 29-36.
4. Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord 2014;14:121.
5. Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther 2014;28: 281-9.
6. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014;8:554-61.
7. Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascularrisk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol 2014; 37:597-604.
8. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014;168:682-9.
9. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/ kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711-5.
10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19.
11. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129:234-43.